David S Rickman

10PUBLICATIONS
77CO-AUTHORS
Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jun 22, 2026
ERG orchestrates a dedifferentiation-senescence-inflammation triad in prostate cancer.

|Feb 20, 2026
Crosstalk between EZH2 and DNA methylation mediates neuroendocrine prostate cancer lineage plasticity.

Richa Singh, Varadha Balaji Venkadakrishnan, Eddie Imada

|Mar 19, 2025
Targeting anti-androgen therapy resistance through epigenetic rewiring.

Kate E Dunmore, David S Rickman

|Nov 20, 2024
Increased translation driven by non-canonical EZH2 creates a synthetic vulnerability in enzalutamide-resistant prostate cancer.

Shankha S Chatterjee, Juan F Linares, Tania Cid-Diaz

|Aug 08, 2024
Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes.

Varadha Balaji Venkadakrishnan, Adam G Presser, Richa Singh

|Feb 26, 2024
Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes.

Varadha Balaji Venkadakrishnan, Adam G Presser, Richa Singh

Pageof 2

Frequent Collaborators

7 joint publications

Himisha Beltran

5 joint publications

Nicholas J Brady

5 joint publications

Brian Robinson

4 joint publications

Varadha Balaji Venkadakrishnan